Global Allergy Diagnostics and Therapeutics Market Size, Share, Analysis, Trends, 2032

Allergy Diagnostics and Therapeutics Industry Prospective:

The global allergy diagnostics and therapeutics market size was worth around USD 33.5 billion in 2023 and is predicted to grow to around USD 70.8 billion by 2032, with a compound annual growth rate (CAGR) of roughly 8.7% between 2024 and 2032.

   Request Free Sample

Allergy Diagnostics and Therapeutics Market: Overview

Allergy diagnostics refers to the methods and procedures applied to identify the exact allergens triggering a person to experience hypersensitive reactions and diagnose allergic diseases. Skin prick tests (SPT), blood tests, and patch testing are popular allergy diagnostics.

Furthermore, allergy therapeutics center on controlling and curing allergic conditions by either immunotherapy or medication, lowering or eradicating symptoms. This involves biologics, medication, and allergen immunotherapy (AIT). These approaches try to improve the quality of life for people with allergies by lowering symptoms and preventing difficulties.

Key Insights

• As per the analysis shared by our research analyst, the global allergy diagnostics and therapeutics market is estimated to grow annually at a CAGR of around 8.7% over the forecast period (2024-2032).
• In terms of revenue, the global allergy diagnostics and therapeutics market size was valued at around USD 33.5 billion in 2023 and is projected to reach USD 70.8 billion by 2032.
• The increasing product approval is expected to drive the allergy diagnostics and therapeutics market over the forecast period.
• Based on type, the therapeutics segment is expected to dominate the market over the forecast period.
• Based on allergen type, the inhaled segment is expected to hold the largest market share over the forecast period.
• Based on test type, the in vitro test segment is expected to hold the largest market share over the forecast period.
• Based on region, North America is expected to dominate the market during the forecast period.

Allergy Diagnostics and Therapeutics Market: Growth Drivers

The high prevalence of allergies drives market growth

The allergy diagnostics and therapeutics industry is primarily fueled by the increasing prevalence of allergies. Many high-risk factors can lead to chronic respiratory disorders, including occupational exposure and growing indoor & outdoor air pollution. Allergies are much more common in metropolitan than rural areas due to their greater exposure to environmental pollutants brought on by industrialization and urbanization.

One in four children and one in three adults in the United States have seasonal allergies, according to World Health Organization (WHO) published data in January 2023. About 6% of US children and adults have food allergies; Black, Asian, and Hispanic persons have the highest incidence.

Allergy Diagnostics and Therapeutics Market: Restraints

Complexity in allergy classification hinders market growth

Grouping patients for particular treatments and spotting allergic reaction patterns to enhance diagnosis, prognosis, and treatment are two of the most difficult tasks in allergy research. It is more difficult to treat allergies when there are multiple endotypes with the same or different characteristics from infancy. Additionally, many kids have several allergies at once, which makes it more difficult to provide appropriate therapy. The market for allergy diagnostics and treatments is not growing as a whole because of these issues, which restrict advancements in diagnosis and therapy.

Allergy Diagnostics and Therapeutics Market: Opportunities

Increasing product approval offers a lucrative opportunity for market growth

The increasing product approval is expected to offer a lucrative opportunity to the allergy diagnostics and therapeutics market during the analysis period. For instance, in January 2023, the U.S. Food and Drug Administration (FDA) approved ODACTRA® (House Dust Mite Allergen Extract) Tablet for Sublingual Use for the treatment of house dust mite (HDM)-induced allergic rhinitis in individuals aged 12 to 17. This news was released by ALK, a multinational pharmaceutical company focused on the prevention, diagnosis, and treatment of allergies and is driven by research.

Allergy Diagnostics and Therapeutics Market: Challenges

The scarcity of qualified healthcare professionals poses a major challenge to market expansion

One major factor impeding the expansion and accessibility of the allergy diagnostics and therapeutics market is the scarcity of qualified healthcare professionals. Specialists like allergists and immunologists are needed to diagnose and treat allergies, particularly complex disorders like food allergies, asthma, and immunotherapy. These qualified experts are in low supply in many areas, especially rural and neglected communities. This postpones diagnosis and treatment and restricts access to quality care.

Additionally, allergy diagnostics requires specialized knowledge and abilities, especially in more complex methods like skin testing, blood testing, and result interpretation. Similarly, allergy treatments like immunotherapy and biologics call for specific knowledge. A shortage of trained professionals may result from inadequate programs or training gaps that teach healthcare providers in these specific fields.

Allergy Diagnostics and Therapeutics Market: Report Scope

Allergy Diagnostics and Therapeutics Market: Segmentation

The global allergy diagnostics and therapeutics industry is segmented based on type, allergen type, test type, and region.

Based on type, the global allergy diagnostics and therapeutics market is segmented into diagnostics and therapeutics. The therapeutics segment is expected to dominate the market over the forecast period because it focuses on treating allergies. Therapeutics seek to address patients' primary concerns by reducing symptoms and offering relief from allergies. Due to its strong and quick reaction, as well as its quick effect during severe allergic reactions like anaphylaxis, epinephrine dominated the market as a whole. Being a natural hormone, it quickly relieves symptoms like low blood pressure and respiratory distress by stimulating the body's fight-or-flight reaction. It is a vital and reliable tool in emergency allergy care because of its widespread use, affordability, and decades-long proven use.

Based on the allergen type, the global allergy diagnostics and therapeutics industry is bifurcated into food, inhaled, drug, and other allergens. The inhaled segment is expected to hold the largest market share over the forecast period due to the rising prevalence of respiratory allergies brought on by air pollution and industrialization. Estimates released by the Allergy and Asthma Foundation of America predicted that 81 million Americans would suffer from seasonal allergic rhinitis. This equates to almost 26% (67 million) of adults and 19% (14 million) of children, which is anticipated to increase during the projected period. Therefore, it is expected that the rising prevalence of allergic rhinitis will offer prospects for market expansion in the future.

Based on the test type, the global allergy diagnostics and therapeutics market is bifurcated into in vivo tests and in vitro tests. The in vitro test segment is expected to dominate the market during the forecast period. Immunoglobulin E (IgE) specific to allergens is identified with this assay. When it comes to identifying aeroallergen (pollen and insect) sensitization, serum IgE has a higher positive predictive value and superior specificity. Throughout the projected period, these variables may have a major impact on the market penetration of allergy diagnostics.

Allergy Diagnostics And Therapeutics Market: Regional Analysis

North America dominates the market over the projected period

North America is expected to dominate the global allergy diagnostics and therapeutics market during the forecast period. The regional expansion is driven by increased allergy rates and attractive regional government efforts. North America is a developed region with high healthcare costs. The region had a significant market share due to a better knowledge of the great potential associated with allergy medications. This has prompted US-based companies to make significant expenditures in the development of these medications.

Furthermore, new competitors are entering the market with innovative products, which is projected to increase fierce rivalry in the North American industry.

Allergy Diagnostics and Therapeutics Market: Competitive Analysis

The global allergy diagnostics and therapeutics market is dominated by players like:

• R-Biopharm AG
• Thermo Fisher Scientific Inc.
• DASIT Group SPA
• EUROIMMUN Medizinische Labordiagnostika AG (PerkinElmer Inc.)
• AESKU.GROUP GmbH
• bioMérieux
• Siemens Healthcare GmbH
• Stallergenes Greer
• HYCOR Biomedical
• Minaris Medical America Inc.
• Omega Diagnostics Group PLC
• Lincoln Diagnostics Inc.
• HOB
• Biotech Group Corp. Ltd.
• Danaher
• Alcon
• AbbVie Inc.
• Sanofi
• Allergy Therapeutics
• Pfizer Inc.
• Teva Pharmaceutical Industries Ltd.
• GSK plc

The global allergy diagnostics and therapeutics market is segmented as follows:

By Type

• Diagnostics
• Therapeutics

By Allergen Type

• Food
• Inhaled
• Drug
• Other Allergens

By Test Type

• In vivo Test
• In vitro Test

By Region

• North America
  • The U.S.
  • Canada
• Europe
  • France 
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of Middle East & Africa